Biogen sees two phase 2 failures: In sciatica and in its lupus collaboration with UCB

UCB and Biogen’s lupus drug dapirolizumab pegol failed to clear a phase 2b study, missing its primary endpoint in dose responses compared to placebo.

In addition, Biogen disclosed that it discontinued development of its vixotrigine treatment for sciatic nerve pain in the lower back and legs, after a separately poor phase 2b showing.